INAB (IN8bio) Net Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IN8bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. IN8bio's Net Income for the three months ended in Dec. 2024 was $-6.16 Mil. IN8bio's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, IN8bio's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for IN8bio's Net Margin % or its related term are showing as below:

INAB's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -126.37
* Ranked among companies with meaningful Net Margin % only.

IN8bio Net Margin % Historical Data

The historical data trend for IN8bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio Net Margin % Chart

IN8bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Margin %

Get a 7-Day Free Trial

IN8bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IN8bio's Net Margin %

For the Biotechnology subindustry, IN8bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where IN8bio's Net Margin % falls into.

Save Embed

;

Save Embed

;

IN8bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

IN8bio's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-30.437	/	0
	=	%

IN8bio's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-6.16	/	0
	=	%

IN8bio (NAS:INAB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

IN8bio Net Margin % Related Terms

Thank you for viewing the detailed overview of IN8bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IN8bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

6JH:Germany

Address

350 5th Avenue, Suite 5330, New York, NY, USA, 10118

Website

https://www.in8bio.com

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Executives

Jeremy R. Graff	director	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall	officer: Chief Financial Officer	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho	director, officer: President, CEO and CFO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l.	director, 10 percent owner	40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc	10 percent owner	10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb	officer: EVP and CSO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami	officer: Chief Medical Officer	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin	officer: Chief Operating Officer	IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118